



PRM Resolve

Pro-Resolving Mediators*

PRM Resolve is a potent proprietary formula providing pro-resolving lipid mediators (PRMs) to encourage specialized pro-resolving mediator (SPM) production in the body. SPMs are the result of PRMs, so ingesting more PRMs leads to producing more SPMs. The benefits of more SPMs may include the support of healthy blood lipid and lipid mediator profiles, promote healthy heart function, and support a balanced immune response.*^{1,2,3,4}

SPM production is affected by several factors, particularly nutrition, health status, genetics, and lifestyle. When the body detects an imbalance, an immune response is initiated and is followed by a resolution to the issue. Low SPM production may hinder the body's ability to effectively resolve an immune response, thereby impacting health and well-being.⁵ Supplementing with PRM Resolve is a prudent and efficacious choice for supporting the resolution of immune responses in the body.*

PRM Resolve is formulated with the highest concentration of marine lipids available on the market today.* With 2.1 grams of marine lipid concentrate and 1,200 mg of Omega-3 fatty acids from EPA, DHA, and additional Omega-3's, PRM Resolve is double the potency and significantly more cost-effective than other leading brands.

How PRM Resolve Works

PRMs are metabolites of EPA, DHA and DPA. The most abundant metabolites being 14-HDHA, 17-HDHA and 18-HEPE. These metabolites and other similar compounds are further metabolized to form various classes of Specialized Pro Resolving Mediators (SPMs).

SPMs are reduced lipid signaling agents that are known to uniquely promote the resolution of inflammation and to promote the general well-being by positively interacting with various types of immune cells.*^{6,7} These signaling molecules include lipoxins, resolvins, maresins, and protectins.

Elevated SPM requirements due to injury, trauma, or chronic inflammation, may not be adequately met based upon omega-3 status, biochemical individuality, or host lifestyle issues.*⁸ Including PRM metabolites along with Omega-3 fatty acids is emerging as a promising modality to support the healthy formation of SPMs required for homeostasis and promote healthy immune activity.*⁹

PRM Resolve Supplementation

Emerging research shows that PRMs and their metabolite SPMs facilitate many cellular and biological functions traditionally attributed to Omega-3s.* Studies indicate these compounds may have a vast range of potential benefits including cardiovascular, neurological, immunological, and cognitive health.*

Key benefits and quality differences of supplementation with PRM Resolve's market-leading proprietary formula include:

- Supports a healthy blood lipid profile*¹
- Supports unique lipid mediator profiles*²
- Supports healthy functioning of the heart*³
- Promotes balanced immune activity and homeostasis*⁴
- Helps improve Omega-3 status*⁹



Form: 60/120 Softgels

Serving Size: 2 Softgels

Ingredients	Amount	%DV
Calories	25	
Total Fat	2 g	3%*
Cholesterol	10 mg	3%*
Protein	<1 g	
Marine Lipid Concentrate	2.1 g	**
Total Omega-3 Fatty Acids	1,200 mg	**
EPA (Eicosapentaenoic Acid)	580 mg	**
DHA (Docosahexaenoic Acid)	420 mg	**
Additional Omega-3 Fatty Acids	200 mg	**
Total PRMs (including 18-HEPE, 17-HDHA, and 14-HDHA)	400 mcg	**

Other Ingredients:

Highly concentrated omega-3 marine oil (anchovy, sardine, squid, and mackerel), capsule shell (gelatin, glycerin, purified water), natural lemon flavor, natural mixed tocopherols.

Contains: Fish (anchovy, sardine, squid, and mackerel).

Directions:

Take two softgels daily or as directed by your healthcare practitioner.

Caution: If pregnant, nursing, or taking nutritional supplements or medications, consult your healthcare practitioner before use. Keep out of reach of children.



* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

References:

1. Skulas-Ray, A. C., Flock, M. R., Richter, C. K., Harris, W. S., West, S. G., & Kris-Etherton, P. M. (2015). Red blood cell docosapentaenoic acid (DPA n-3) is inversely associated with triglycerides and C-reactive protein (CRP) in healthy adults and dose-dependently increases following n-3 fatty acid supplementation. *Nutrients*, 7(8), 6390-6404.
2. Markworth, J. F., Kaur, G., Miller, E. G., Larsen, A. E., Sinclair, A. J., Maddipati, K. R., & Cameron-Smith, D. (2016). Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid. *The FASEB Journal*, 11, 3714-3725.
3. Rissanen, T., Voutilainen, S., Nyyssönen, K., Lakka, T. A., & Salonen, J. T. (2000). Fish oil-derived fatty acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events: The Kuopio ischaemic heart disease risk factor study. *Circulation*, 102(22), 2677-2679.
4. Serhan, C. N., Chiang, N., & Dalli, J. (2015). The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. *Seminars in Immunology*, 27(3), 200-215.
5. Bannenberg, G., & Serhan, C. N. (2010). Specialized pro-resolving lipid mediators in the inflammatory response: An update. *Molecular and Cell Biology of Lipids*, 1801(12), 1260-1273.
6. Serhan, C. N., & Chiang, N. (2008). Endogenous pro-resolving and anti-inflammatory lipid mediators: A new pharmacologic genus. *British Journal of Pharmacology*, 153(S1), S200-S215.
7. Serhan, C. N., Krishnamoorthy, S., Recchiuti, A., & Chiang, N. (2011). Novel anti-inflammatory-pro-resolving mediators and their receptors. *Current Topics in Medicinal Chemistry*, 11(6), 629-647.
8. Serhan, C. N., & Chiang, N. (2013). Resolution phase lipid mediators of inflammation: Agonists of resolution. *Current Opinion in Pharmacology*, 13(4), 632-640.
9. Linderborg, K. M., Kaur, G., Miller, E., Larsen, A. E., Weir, J. M., Nuora, A., Barlow, C. K., Kallio, H. P., Cameron-Smith, D., & Sinclair, A. J. (2013). Postprandial metabolism of docosapentaenoic acid (DPA, 22:5n-3) and eicosapentaenoic acid (EPA, 20:5n-3) in humans. *Prostaglandins, Leukotrienes & Essential Fatty Acids*, 88(4), 313-319.